Free Trial
→ The real reason gold is soaring (and likely to continue) (From Golden Portfolio) (Ad)
OTCMKTS:ZLDPF

Zealand Pharma A/S 5/11/2023 Earnings Report

Zealand Pharma A/S logo
$64.82 -1.30 (-1.96%)
As of 04/17/2025 11:06 AM Eastern
Earnings HistoryForecast

Zealand Pharma A/S EPS Results

Actual EPS
-$0.54
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Zealand Pharma A/S Revenue Results

Actual Revenue
$1.96 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Zealand Pharma A/S Announcement Details

Quarter
Date
5/11/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Zealand Pharma A/S' next earnings date is estimated for Wednesday, May 7, 2025, based on past reporting schedules.

Conference Call Resources

Zealand Pharma A/S Earnings Headlines

Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2025
April 19 at 11:33 PM | finance.yahoo.com
Zealand Pharma Goes on Hiring Spree as It Gears Up for Obesity Tie-Up With Roche
April 11, 2025 | wsj.com
Trump and Musk fight back
Is there more to the Musk–Trump relationship than meets the eye? Jeff Brown thinks so — and he believes it has to do with a top-level initiative to build the ultimate military-grade AI system. He’s calling it the “AI Superweapon,” and he says it could soon become the center of global tech dominance. At the core of this initiative? A handful of companies tied to America’s most powerful tech platforms — and investors who act before this goes mainstream may have a rare early edge.
April 20, 2025 | Brownstone Research (Ad)
Gubra’s obesity drug trial success weighs on Zealand Pharma stock
April 2, 2025 | investing.com
Zealand Pharma upgraded to Overweight from Equal Weight at Morgan Stanley
March 21, 2025 | markets.businessinsider.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Vicarious Surgical (RBOT), Alkermes (ALKS) and Zealand Pharma (OtherZLDPF)
March 18, 2025 | markets.businessinsider.com
See More Zealand Pharma A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zealand Pharma A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zealand Pharma A/S and other key companies, straight to your email.

About Zealand Pharma A/S

Zealand Pharma A/S (OTCMKTS:ZLDPF), a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

View Zealand Pharma A/S Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles